MARLBOROUGH, Mass., Oct. 2, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ending September 30, 2023, on Thursday, October 26, 2023, at 8:00 a.m. EDT. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the third quarter on October 26 prior to the conference call.
A live webcast and replay of the webcast will be accessible at https://investors.bostonscientific.com. The replay will be available approximately one hour following the completion of the event.
About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.
CONTACTS:
Media:
Katie Schur
508-683-5574 (office)
Media Relations
Boston Scientific Corporation
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations:
Lauren Tengler
508-683-4479 (office)
Investor Relations
Boston Scientific Corporation
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$103.83 |
Daily Change: | -0.49 -0.47 |
Daily Volume: | 5,490,169 |
Market Cap: | US$153.670B |
July 07, 2025 April 23, 2025 March 03, 2025 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load